Regulation of GABA(A) receptor α1 protein is a sensitive indicator of benzodiazepine agonist efficacy

European Journal of Pharmacology

Volumn 348, Issue 2-3, 1998, Pages 321-324

  Johnston, Jonathan D ^a   Bristow, David R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Benzodiazepine; Cerebellar granule cell; Partial agonist; Protein regulation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 CHLORO 3 [3 (CYCLOPROPYLMETHOXY) 1 PROPYNYL] 4,5 DIHYDRO 5 METHYL 6H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; 7 CHLORO 4,5 DIHYDRO 3 (3 HYDROXY 1 PROPYNYL) 5 METHYL 6H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; DIAZEPAM; FLUNITRAZEPAM; IMIDAZENIL; RECEPTOR PROTEIN; RO 19 8022; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG EFFICACY; GRANULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CELLS, CULTURED; CEREBELLUM; DIAZEPAM; FLUNITRAZEPAM; GABA MODULATORS; PYRROLIDINES; QUINOLIZINES; RATS; RECEPTORS, GABA-A;

EID: 0032496082     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00259-3     Document Type: Article

References (20)

1. Bronson M.E. Chronic bretazenil produces tolerance to chlordiazepoxide, midazolam, and abecarnil. Pharmacol. Biochem. Behav. 51:1995;481-490.
2. 1 subunit protein in rat cerebellar granule cells. Br. J. Pharmacol. 118:1996;1103-1110.
3. Costa E., Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. 17:1996;192-200.
4. Delini-Stula A. Bretazenil: clinical experience. Neurosci. Facts. 3:1992;72.
5. A receptors. Eur. J. Pharmacol. 244:1993;29-35.
6. Ehlert F.J. 'Inverse agonists', cooperativity and drug action at benzodiazepine receptors. Trends Pharmacol. Sci. 7:1986;28-32.
7. Facklam M., Schoch P., Haefely W.E. Relationship between benzodiazepine receptor occupancy and potentiation of γ-aminobutyric acid-stimulated chloride flux in vitro of four ligands of differing intrinsic efficacies. J. Pharm. Exp. Ther. 261:1992;1106-1112.
8. Fleischhacker W.W. Dependence potential of benzodiazepines. Lancet. ii:1988;504.
9. Haefely W., Martin J.R., Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11:1990;452-456.
10. Hernandez T.D., Heninger C., Wilson M.A., Gallager D.W. Relationship of agonist efficacy to changes in GABA sensitivity and anticonvulsant tolerance following chronic benzodiazepine ligand exposure. Eur. J. Pharmacol. 170:1989;145-155.
11. A receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol. 49:1996;822-831.
12. Jenck F., Moreau J.-L., Bonetti E.P., Martin J.R., Haefely W.E. Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J. Pharm. Exp. Ther. 262:1992;1121-1127.
13. Martin J.R. Preclinical dependence liability of benzodiazepine receptor partial agonists. Eur. Neuropsychopharmacol. 3:1993;270-271.
14. Martin J.R., Schoch P., Jenck F., Moreau J.-L., Haefely W.E. Pharmacological characterisation of benzodiazepine ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology. 111:1993;415-422.
15. A receptor α subunits in rat brain during development. FEBS Lett. 286:1991;44-46.
16. A receptor subunit expression in rat neocortical areas. Neuroscience. 79:1997;477-487.
17. A receptor function. J. Pharmacol. Exp. Ther. 269:1994;32-38.
18. A receptor subtypes. Pharmacol. Rev. 47:1995;181-234.
19. Van Steveninck A.L., Gieschke R., Schoemaker R.C., Roncari G., Tuk B., Pieters M.S.M., Breimer D.D., Cohen A.F. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol. 41:1996;565-573.
20. Zanotti A., Mariot R., Contarino A., Lipartiti M., Giusti P. Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats. Br. J. Pharmacol. 117:1996;647-652.